buserelin on central precocious puberty to its excretion in urine, as a parameter of metabolism or compliance, we have studied 52 patients treated either sc or intranasally. In girls with good control, urinary buserelin excretion represented 0.5 \m=+-\0.1% of the daily intranasal dose vs 12.5 \m=+-\2.3% of the daily sc dose. In boys, it represented 0.8 \m=+-\0.2 and 9.9 \m=+-\2.7%, respectively. In the sc treated group, 3 patients (2 girls and 1 boy) with poor control who exhibited excretion levels similar to those with good control were classified as resistant to therapy. Clinical control was poor in 4 intranasally treated girls: 2 had low excretion values suggesting poor compliance or failure of absorption by the nasal mucosa, and 2 appeared resistant to therapy, as urinary excretion levels of buserelin were similar to those of well-controlled patients. In (6) .
The effectiveness of this treatment with GnRH agonists was tested in precocious puberty by several investigators and gave promising results, particu¬ larly as to decreasing growth rate (7) (8) (9) . However, an escape from initial pituitary gonadal suppres¬ sion or a refractoriness to suppression was ob¬ served by several authors in gonadotropin-independent sexual precocity or in some cases of the McCune-Albright syndrome (10, 11) , the mecha¬ nisms of which are unknown. Bad compliance may also be related to this escape phenomenon, in par¬ ticular when using intranasal administration of the agonist. In order to monitor therapy with the GnRH agonist buserelin in precocious puberty, measure¬ ments of urinary excretion of the immunoreactive agonist were undertaken with the collaboration of several European centres which have investigated the long-term effects of this GnRH agonist on cen¬ tral precocious puberty (3, 12, 13) 
Radioimmunological measurements
Immunoreactive buserelin and its C-terminal metabolites in urine were measured using a recently described method (14 (14) . In the case of intranasal administration, measurement of urinary ex¬ cretion of buserelin was useful for establishing the diagnosis of resistant forms as observed in patients with the McCune-Albright syndrome (with low go¬ nadotropin levels) or with gonadotropin-independent Leydig cell hyperplasia (10, 11) , or for estab¬ lishing an escape phenomenon after initial sup¬ pression. Measurement of urinary excretion of bu¬ serelin is useful for differentiating resistance from poor compliance or low absorption of buserelin by the nasal mucosa. It has been shown that experi¬ mental rhinitis does not affect the absorption of buserelin (22) , and clinical observations suggest that a common cold or allergic rhinitis does not affect absorption.
As already observed (14) , there is a marked dif¬ ference in absorption and excretion of buserelin given sc and in, using comparable daily doses (23 to 42 pg/kg). This is so because the absorption of oligopeptides such as buserelin by the nasal mucosa is limited (23, 24) . However, the good clinical control of most of these intranasally treated patients sug¬ gests that a limited amount of the agonist reaches the pituitary gland without any significant firstpass effect in the systemic circulation. Anatomi¬ cally, there is no direct vascular connection between the nasal mucosa and the pituitary gland. One could imagine a simple diffusion of the peptide through the lamina criblata and some small re¬ cesses of the meningeal tissue and then, through the vascular endothelium of the hypothalamo-pituitary portal system. One could also imagine that the peptide could diffuse to the olfactory lobes or to the terminal nerve, a cranial nerve which is part of the accessory olfactory system and embryologically projects from the nose to the septal-preoptic nuclei in the brain and contains GnRH immunofluorescence (25) . Whether buserelin can induce desensitization of these neurones remains to be proven. Whatever the mechanism is, the small amount of peptide absorbed is sufficient for a the¬ rapeutical effect and gives validity to the use of the intranasal route for administration of small hor¬ monal peptides acting on the pituitary gonadotropes.
